## Sébastien Andre

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6005151/publications.pdf

Version: 2024-02-01

21 papers 1,219 citations

471509 17 h-index 677142 22 g-index

22 all docs 22 docs citations

times ranked

22

2082 citing authors

#	Article	IF	CITATIONS
1	T Cell–Derived IL-22 Amplifies IL-1β–Driven Inflammation in Human Adipose Tissue: Relevance to Obesity and Type 2 Diabetes. Diabetes, 2014, 63, 1966-1977.	0.6	197
2	Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. Cell Metabolism, 2015, 22, 113-124.	16.2	130
3	Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nature Communications, 2020, 11, 5881.	12.8	122
4	A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8965-8970.	7.1	110
5	Immune cell-derived cytokines contribute to obesity-related inflammation, fibrogenesis and metabolic deregulation in human adipose tissue. Scientific Reports, 2017, 7, 3000.	3.3	106
6	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. Journal of Allergy and Clinical Immunology, 2019, 143, 1575-1585.e4.	2.9	86
7	T Cell Populations and Functions Are Altered in Human Obesity and Type 2 Diabetes. Current Diabetes Reports, 2017, 17, 81.	4.2	71
8	Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism. Gut, 2022, 71, 2463-2480.	12.1	53
9	Senescence-associated $\hat{l}^2$ -galactosidase in subcutaneous adipose tissue associates with altered glycaemic status and truncal fat in severe obesity. Diabetologia, 2021, 64, 240-254.	6.3	45
10	AhR activation defends gut barrier integrity against damage occurring in obesity. Molecular Metabolism, 2020, 39, 101007.	6.5	42
11	Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica, 2007, 92, 1423-1426.	3.5	40
12	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood, 2011, 117, 2257-2264.	1.4	38
13	Mucosalâ€associated invariant T (MAIT) cells are depleted and prone to apoptosis in cardiometabolic disorders. FASEB Journal, 2018, 32, 5078-5089.	0.5	37
14	Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica, 2008, 93, 83-89.	3.5	34
15	A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. Clinical Reviews in Allergy and Immunology, 2009, 37, 105-113.	6.5	24
16	Functional variability of antibodies upon oxidative processes. Autoimmunity Reviews, 2008, 7, 574-578.	5.8	18
17	Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. Journal of Immunology, 2008, 181, 1609-1615.	0.8	18
18	Discontinuous epitopes on the C2 domain of coagulation Factor VIII mapped by computerâ€designed synthetic peptides. British Journal of Haematology, 2011, 155, 487-497.	2.5	16

## SéBASTIEN ANDRE

#	Article	IF	CITATIONS
19	Adipose tissue adaptive response to <i>trans</i> ‶0, <i>cisâ€</i> 12 onjugated linoleic acid engages alternatively activated M2 macrophages. FASEB Journal, 2016, 30, 241-251.	0.5	12
20	Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. Molecular Immunology, 2014, 60, 54-61.	2.2	9
21	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology, 2009, 47, 290-297.	2.2	6